ADAPTIVE BIOTECHNOLOGIES CORPORATION: 10-Q filed 2024-05-07
What ADAPTIVE BIOTECHNOLOGIES CORPORATION reported in its quarterly report filed 2024-05-07 (fiscal Q1 2024): 46 published measures, 93 facts as tagged in accession 0000950170-24-054604.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-05-07
- Fiscal period
- fiscal Q1 2024
- Accession
- 0000950170-24-054604 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ADAPTIVE BIOTECHNOLOGIES CORPORATION filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 620,323,000 | USD | |
| At 2023-12-31 | 661,134,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 345,557,000 | USD | |
| At 2023-12-31 | 352,856,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 274,913,000 | USD | |
| At 2023-12-31 | 308,399,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 71,233,000 | USD | |
| At 2023-12-31 | 65,064,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -47,507,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -57,699,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -38,353,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -59,152,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 1,511,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 2,924,000 | USD | 90 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 41,873,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 37,647,000 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 44,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 672,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 44,509,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 62,979,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | -1,191,839,000 | USD | |
| At 2023-12-31 | -1,144,332,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 145,787,527 | shares | 91 |
| 2023-01-01 to 2023-03-31 | 143,511,142 | shares | 90 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 145,787,527 | shares | 91 |
| 2023-01-01 to 2023-03-31 | 143,511,142 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -0.33 | USD/shares | 91 |
| 2023-01-01 to 2023-03-31 | -0.4 | USD/shares | 90 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -0.33 | USD/shares | 91 |
| 2023-01-01 to 2023-03-31 | -0.4 | USD/shares | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 65,260,000 | USD | |
| At 2023-12-31 | 68,227,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 14,298,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 14,671,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -48,762,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -57,193,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 374,034,000 | USD | |
| At 2023-12-31 | 410,188,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 2,993,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 3,531,000 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 82,952,000 | USD | |
| At 2023-12-31 | 88,015,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 12,170,000 | USD | |
| At 2023-12-31 | 7,719,000 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 118,972,000 | USD | |
| At 2023-12-31 | 118,972,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 4,705,000 | USD | |
| At 2023-12-31 | 5,128,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 42,021,000 | USD | |
| At 2023-12-31 | 37,969,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 13,291,000 | USD | |
| At 2023-12-31 | 14,448,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 30,245,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 32,601,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 147,368,324 | shares | |
| At 2023-12-31 | 145,082,271 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 1,466,844,000 | USD | |
| At 2023-12-31 | 1,452,502,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | -106,000 | USD | |
| At 2023-12-31 | 215,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 274,766,000 | USD | |
| At 2023-12-31 | 308,278,000 | USD | |
| At 2023-03-31 | 423,952,000 | USD | |
| At 2022-12-31 | 464,098,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 50,999,000 | USD | |
| At 2023-12-31 | 52,096,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 96,494,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 3,390,000 | USD | |
| At 2023-12-31 | 3,591,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 7,914,000 | USD | |
| At 2023-12-31 | 8,597,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 9,850,000 | USD | |
| At 2023-12-31 | 11,370,000 | USD |
Current contract liabilities
Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-03-31 | 46,870,000 | USD | |
| At 2023-12-31 | 48,630,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -47,533,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -57,700,000 | USD | 90 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -47,828,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -55,488,000 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 19,597,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 20,831,000 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 4,791,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 5,004,000 | USD | 90 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 423,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 419,000 | USD | 90 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 2,289,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 2,760,000 | USD | 90 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 3,700,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 3,400,000 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | 4,052,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -9,085,000 | USD | 90 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-03-31 | -1,111,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | 6,607,000 | USD | 90 |
Inspect the source
- Entity
- ADAPTIVE BIOTECHNOLOGIES CORPORATION / CIK 0001478320
- Captured
- 2026-09-20T09:08:39.352Z
- SEC response SHA-256
2deab3b0302b42f5bca7f049684da17a3e834dfbc3dbe128e51ed398b3d69a92
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001478320.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))